In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Business Strategies Platform Technologies

A Two Pharma Horse Race In Follow-On Biologics

Executive Summary

In the horse race to develop follow-on biologics, there are two companies vying for the pole position: Teva Pharmaceutical Industries Ltd. and Merck & Co. Inc. Even as other pharmaceutical companies weigh the merits of building FOB capabilities, these two companies are demonstrating their commitment not just with words but with cold, hard cash.
Table

View full table

Advertisement

Related Content

In Vivo
Your First Drug's Approved and Launched...Now What?
In Vivo
Your First Drug's Approved and Launched...Now What?
In Vivo
Opening A Door To Biosimilars In The US
In Vivo
Opening A Door To Biosimilars In The US
In Vivo
Health Care Reform: For Biopharmas There Is Much To Like
In Vivo
Health Care Reform: For Biopharmas There Is Much To Like
In Vivo
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
In Vivo
Merck's Head-long Leap into Follow-On Biologics
In Vivo
Merck's Head-long Leap into Follow-On Biologics
In Vivo
Pharma's New Follow-On Strategy

Topics

Related Companies

Related Deals

Advertisement
Tags:
BioPharmaceutical Business Strategies Platform Technologies
UsernamePublicRestriction

Register

IV003247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By